Should You Buy Twist Bioscience Corp (TWST) Today? Analysis, Price Targets, and 2026 Outlook.
Conclusion
Hold
Latest Price
42.010
1 Day change
-1.38%
52 Week Range
54.740
Analysis Updated At
2026/01/26
Twist Bioscience Corp (TWST) is not a strong buy for a beginner investor with a long-term strategy at this moment. While there are positive trends in revenue growth and analyst sentiment, the stock faces significant insider and hedge fund selling, weak financial performance with declining net income and EPS, and no strong proprietary trading signals. The current pre-market price is slightly down, and technical indicators are mixed, suggesting no immediate urgency to buy.
Technical Analysis
The stock shows bullish moving averages (SMA_5 > SMA_20 > SMA_200), a positive MACD histogram of 0.655, and RSI at 65.741 in the neutral zone. Key resistance levels are at R1: 44.69 and R2: 47.261, while support levels are at S1: 36.366 and S2: 33.795. The technical setup suggests moderate bullish momentum but no strong buy signal.
Options Data
Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio
Technical Summary
Sell
3
Buy
7
Positive Catalysts
Revenue increased by 16.88% YoY in Q4
Gross margin improved to 51.35%, up 13.78% YoY.
Analysts have raised price targets recently, with TD Cowen setting a target of $43 and Evercore ISI at $42, both maintaining positive ratings.
Neutral/Negative Catalysts
Hedge funds and insiders are heavily selling, with insider selling up 1408.31% in the last month and hedge fund selling up 634.68% in the last quarter.
Net income dropped by -21.69% YoY, and EPS fell by -23.73% YoY in Q4
No recent news or significant event-driven catalysts.
No proprietary trading signals from AI Stock Picker or SwingMax.
Financial Performance
In Q4 2025, revenue increased to $99.009M, up 16.88% YoY, and gross margin improved to 51.35%, up 13.78% YoY. However, net income declined to -$27.138M, down -21.69% YoY, and EPS dropped to -0.45, down -23.73% YoY. The company continues to face profitability challenges.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
Analysts are generally positive on TWST, with recent price target increases from TD Cowen ($43), Evercore ISI ($42), and Barclays ($39). Analysts highlight recovering end markets, sector rotation, and Twist's differentiated DNA synthesis platform as key positives. However, concerns remain about competition and market opportunities in synthetic biology.
Wall Street analysts forecast TWST stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for TWST is 41.25 USD with a low forecast of 39 USD and a high forecast of 43 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
Wall Street analysts forecast TWST stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for TWST is 41.25 USD with a low forecast of 39 USD and a high forecast of 43 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 42.600
Low
39
Averages
41.25
High
43
Current: 42.600
Low
39
Averages
41.25
High
43
Guggenheim
Subbu Nambi
maintain
$42 -> $50
AI Analysis
2026-01-26
New
Reason
Guggenheim
Subbu Nambi
Price Target
$42 -> $50
AI Analysis
2026-01-26
New
maintain
Reason
Guggenheim analyst Subbu Nambi raised the firm's price target on Twist Bioscience to $50 from $42 and keeps a Buy rating on the shares. The firm adjusted models, forecasts and targets for a number of its Diagnostics and Life Sciences Tools covered companies to reflect recent updates and selected pre-announcements of preliminary results last week.
TD Cowen
Buy
upgrade
$32 -> $43
2026-01-08
Reason
TD Cowen
Price Target
$32 -> $43
2026-01-08
upgrade
Buy
Reason
TD Cowen raised the firm's price target on Twist Bioscience to $43 from $32 and keeps a Buy rating on the shares. The firm adjusted price targets in the diagnostic tools group group as part of a Q4 preview. Investor sentiment continues to inflect upward with 2026 guidance updates "key for positioning within the sector recovery," the analyst tells investors in a research note. TD is most positive on stocks "with clear multi-year frameworks and multiple avenues for upside to derisked growth assumptions."
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for TWST
